Eli Lilly CEO explains White House medication cost deal

Market Access & Coverage - Zepbound, a medicine for obesity and overweight, has been inaccessible to many due to cost, highlighting the need for coverage [1] - A new agreement enables coverage for medications like Zepbound for $50 per month, starting next spring [2] - Currently, Medicare beneficiaries pay $500 per month for Zepbound through direct platforms; the new program reduces this cost by 90% to $50 per month [3] Pricing & Affordability - The company defends its pricing strategy by noting that medical products are typically subsidized through medical benefits, from which obesity treatments have historically been excluded [4] - The inclusion of effective and safe obesity medications in medical benefits is advocated, alongside offering better deals to insurance companies [5]